Inhibrx, Inc.
NASDAQ:INBX
Overview | Financials
| Company Name | Inhibrx, Inc. |
| Symbol | INBX |
| Currency | USD |
| Price | 29.1 |
| Market Cap | 421,513,966 |
| Dividend Yield | 0% |
| 52-week-range | 10.805 - 29.385 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Mark Paul Lappe |
| Website | https://inhibrx.com |
An error occurred while fetching data.
About Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD





